Coptisine inhibits neointimal hyperplasia through attenuating Pak1/Pak2 signaling in vascular smooth muscle cells without retardation of re-endothelialization
Yuhan Chen(Pediatric Oncology Group), Yuepeng Wang(Anhui Medical University), Yi‐Gang Li(Shanghai Jiao Tong University), Xueze Jiang(Shanghai Jiao Tong University), Qunshan Wang(Shanghai Jiao Tong University), Xuesheng Hua(XinHua Hospital), Yuchan Yuan(XinHua Hospital), Jie Chen(University of Alberta), Zhiyong Chen(Johns Hopkins University), Yuanyuan Chen(Jahra Hospital), Yi Yu(XinHua Hospital), Hua Liu(Zhejiang A & F University), Qing Zhou(XinHua Hospital), Zhenwei Yang(First Affiliated Hospital of Liaoning Medical University), Julie Wang(Shanghai Jiao Tong University), Ying Yu(Anhui Medical University), Sisi Wei(Hebei Medical University)
Cited by 4
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
|Journal of Allergy and Clinical Immunology|2020|690
Drug allergy: A 2022 practice parameter update
|Journal of Allergy and Clinical Immunology|2022|533